We Need a No-Fault Compensation System for Drug Injuries

The FDA's approval of a prescription drug or biologic is the product of an often-delicate risk-benefit analysis of public benefit as opposed to individual safety. The therapeutic balance of these products must always be weighed against the risks inherent in their use. And there are always inherent risks associated with their use. Accordingly, while millions of Americans reap the benefits of prescription drugs every day, these same drugs may pose an unavoidable health hazard to a narrow, and often unidentifiable, subset of potential users. The American legal system currently regulates these risks by two means ' through the federal regulatory system as administered by the FDA, and through the common-law tort liability regime.

29 minute read September 01, 2003 at 11:01 PM
By
Bert W. Rein, William A. McGrath, and Kristin Davis
We Need a No-Fault Compensation System for Drug Injuries

The FDA's approval of a prescription drug or biologic is the product of an often-delicate risk-benefit analysis of public benefit as opposed to individual safety. The therapeutic balance of these products must always be weighed against the risks inherent in their use.

This premium content is locked for LawJournalNewsletters subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts
Subscribe Now

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

Law Firms Have a Memory Problem Not a Selling Problem

The legal industry continues to treat business development as though it is primarily an attorney behavior issue. It is not. The firm absolutely has the expertise, but what it lacks is retrieval speed and accuracy.

May 31, 2026

Law Firms Don’t Have a Selling Problem, They Have a Memory Problem

The next real divide in the legal market is unlikely to be intelligence. The divide will be between institutions that can reliably retrieve and deploy what they already know and those that cannot. The firms that win will be the ones that can surface the right knowledge, in the right hands, before anyone else does.

May 31, 2026

Work-for-Hire Issue in Litigation Over 'Goosebumps' Musical

A current work-for-hire dispute over rights to the musical adaptation, cast album compositions and sheet music based on the children’s horror novel Goosebumps: Phantom of the Auditorium explores the inter-relationship of work-for-hire and copyright-ownership language in agreements signed both before and after the Goosebumps play was created.

May 31, 2026

Multi-Color and Bankruptcy Venue: New Jersey Bankruptcy Court Adopts “Asset-Based Approach” to “Principal Assets” Under Section 1408

In a closely followed venue dispute, the Bankruptcy Court for the District of New Jersey recently held that venue in the District was proper in the Chapter 11 cases of Multi-Color Corporation and its affiliates. The decision is significant because it offers an analytical framework for determining a debtor’s “principal assets” under section 1408 of the Bankruptcy Code.

May 31, 2026